

ergotamine with caffeine suppository (MIGERGOT)

Diagnoses Considered for Coverage:

- Treatment of moderate to severe migraine headache

Coverage Criteria:

1. For diagnosis of migraine approve if:

- Dose does not exceed FDA label maximum, **and**
- Patient is unable to take or has intolerance to preferred ergotamine-caffeine (Cafergot) tablets.

Coverage Duration: Length of benefit

Effective: 01/01/2022